Anika Therapeutics Q2 revenue rises, lifts 2026 outlook
ANIK•Updated 2026 and 2027 outlook
- Anika raises 2026 total revenue growth outlook to 5%-10%, up from 1%-9%
- Company lifts 2026 adjusted EBITDA margin forecast to 13%-17%, from prior 5%-10%
- Anika cuts 2027 Commercial Channel revenue growth forecast to 5%-15%, from 10%-20%
Drivers of the quarterly results
- Commercial Channel growth - Record Commercial Channel revenue rose 17% yr/yr, driven by strong sales performance
- OEM Channel performance - OEM Channel benefited from strong transfer units, favorable order timing, and Monovisc volume growth
- Gross margin expansion - Higher sales volume, increased manufacturing production, and improved sales mix led to a 65% gross margin
Q2 revenue and profitability improve
- US osteoarthritis solutions maker's Q2 revenue rose 16% yr/yr on record commercial channel sales
- Adjusted EBITDA for Q2 reached $7.1 mln, highest since 2020, with gross margin expanding to 65%
- Company raised 2026 revenue and adjusted EBITDA margin guidance, citing improved operating leverage
